High-dose versus low-dose intravenous iron reduces myocardial infarctions in patients receiving maintenance hemodialysis
WEDNESDAY, Dec. 22, 2021 (HealthDay News) — For patients on maintenance hemodialysis, high-dose versus low-dose intravenous (IV) iron can help reduce the risk for myocardial infarction (MI), according to a study published online Dec. 7 in Cardiovascular Research.
Marc C. Petrie, M.B.Ch.B., from the University of Glasgow in the United Kingdom, and colleagues conducted a prespecified analysis of secondary end points from a randomized clinical trial involving adults who had started hemodialysis within the previous year, had a ferritin concentration <400 µg/L, and had a transferrin saturation <30 percent. A total of 2,141 participants were randomly assigned to either high- or low-dose IV iron.
The researchers found that 8.4 percent of participants experienced an MI during a median follow-up of 2.1 years. The rate of type 1 MIs was higher than the rate of type 2 MIs (3.2 versus 1.3/100 patient-years), and non-ST-elevation MIs were more common than ST-elevation MIs (3.3 versus 0.5/100 patient-years). After nonfatal MI, mortality was high (one- and two-year mortality of 40 and 60 percent, respectively). Compared with reactive low-dose IV iron, proactive high-dose IV iron reduced the composite end point of nonfatal and fatal MI (hazard ratio, 0.69) and nonfatal MI (hazard ratio, 0.69) in time-to-first event analysis. High-dose IV iron had less of an effect on recurrent MI events than on the time-to-first event analysis.
“Very few therapies investigated in people on dialysis have been shown to improve outcomes,” Petrie said in a statement. “Our hope that this treatment is used around the world in people with kidney failure on dialysis.”
Several authors disclosed financial ties to the biopharmaceutical industry; the study was partially funded by Vifor Fresenius Medical Care Renal Pharma.
Cannabis Legalization Linked to More Heart-Related Hospitalizations
Exercise-Based Cardiac Rehab Beneficial for Coronary Heart Disease
UACR, UPCR Provide Indistinguishable Prognostic Information in CKD
Use of SAMA, SABA Linked to Cardiovascular Events, Mortality in Asthma, COPD
Serum Carotenoid Levels Have Positive Impact on COPD Health Status
Air Pollution Does Not Impair Benefits of Walking in Reducing COPD Exacerbation Rate
Lower Cognitive Functioning During 60s Linked to Subsequent Stroke Risk
Elevated C-Reactive Protein Linked to Increased Risk for Incident Heart Failure, All-Cause Mortality